JP2016509222A5 - - Google Patents

Download PDF

Info

Publication number
JP2016509222A5
JP2016509222A5 JP2015556042A JP2015556042A JP2016509222A5 JP 2016509222 A5 JP2016509222 A5 JP 2016509222A5 JP 2015556042 A JP2015556042 A JP 2015556042A JP 2015556042 A JP2015556042 A JP 2015556042A JP 2016509222 A5 JP2016509222 A5 JP 2016509222A5
Authority
JP
Japan
Prior art keywords
acid
subject
biomarkers
level
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015556042A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509222A (ja
JP6404834B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/011759 external-priority patent/WO2014120449A1/en
Publication of JP2016509222A publication Critical patent/JP2016509222A/ja
Publication of JP2016509222A5 publication Critical patent/JP2016509222A5/ja
Application granted granted Critical
Publication of JP6404834B2 publication Critical patent/JP6404834B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015556042A 2013-01-31 2014-01-16 インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法 Active JP6404834B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361758924P 2013-01-31 2013-01-31
US61/758,924 2013-01-31
PCT/US2014/011759 WO2014120449A1 (en) 2013-01-31 2014-01-16 Biomarkers related to insulin resistance progression and methods using the same

Publications (3)

Publication Number Publication Date
JP2016509222A JP2016509222A (ja) 2016-03-24
JP2016509222A5 true JP2016509222A5 (enExample) 2017-02-09
JP6404834B2 JP6404834B2 (ja) 2018-10-17

Family

ID=51262841

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015556042A Active JP6404834B2 (ja) 2013-01-31 2014-01-16 インスリン抵抗性の進行に関連するバイオマーカー及びこれを使用する方法

Country Status (5)

Country Link
US (2) US9910047B2 (enExample)
EP (2) EP3321686B1 (enExample)
JP (1) JP6404834B2 (enExample)
ES (2) ES2669620T3 (enExample)
WO (1) WO2014120449A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105074460B (zh) * 2013-03-28 2018-06-15 雀巢产品技术援助有限公司 作为用于重量增加预防的益生元功效的生物标记物的硫酸吲哚酚
MX2016000293A (es) * 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
CN109154619A (zh) * 2016-05-17 2019-01-04 国立大学法人大阪大学 用于判定糖尿病的血液试样的分析方法及系统
DK3465202T3 (da) * 2016-06-02 2023-08-21 Metabolon Inc Massespektrometrifremgangsmåde til detektering og kvantitering af metabolitter
ES3004083T3 (en) * 2016-12-19 2025-03-11 Metabolon Inc Mass spectrometry assay method for detection and quantitation of kidney function metabolites
WO2018150077A1 (en) * 2017-02-16 2018-08-23 Afekta Technologies Oy Betaine biomarkers for nutritional status, nutritional regimen, endogenous metabolism, or risk of cardiovascular or metabolic diseases
EP4220157B1 (en) 2017-03-31 2025-05-14 Quest Diagnostics Investments LLC Methods for quantitation of insulin and c-peptide
EP3401683A1 (en) * 2017-05-10 2018-11-14 Eberhard Karls Universität Tübingen Medizinische Fakultät Diagnosing metabolic disease by the use of a biomarker
CN111727038B (zh) * 2018-01-17 2025-05-13 南安普顿大学 肌肉减少症和nad缺乏的风险预测及分级方法
JP2022501579A (ja) * 2018-09-27 2022-01-06 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 小児期及び若年成人期においてインスリン抵抗性を発症するリスクについてのマーカー
US11041847B1 (en) * 2019-01-25 2021-06-22 Ixcela, Inc. Detection and modification of gut microbial population
KR102231928B1 (ko) * 2019-09-19 2021-03-26 고려대학교 산학협력단 비만대사수술 이후 당뇨병 예후 예측용 바이오마커 조성물
CA3177108A1 (en) * 2020-04-27 2021-11-04 Wayne R. Matson Detection and modification of gut microbial population
CN112149311B (zh) * 2020-10-12 2021-10-26 北京中恒利华石油技术研究所 一种基于数量规约的非线性多元统计回归测井曲线预测方法
CN112843036A (zh) * 2021-01-29 2021-05-28 中国药科大学 β-羟基丙酮酸在制备人胰岛淀粉样多肽聚集抑制剂中的应用
CN116087486B (zh) * 2021-11-08 2024-02-02 中国医学科学院阜外医院 糖尿病患者早期预测心血管疾病（cvd）的生物标志物及其用途
CN114324662B (zh) * 2021-12-30 2022-09-16 中南大学 用于诊断或预防糖尿病的血清生物标志物的应用
EP4504961A1 (en) * 2022-04-07 2025-02-12 Need4Health B.V. Method for determining insulin dosage
JP7736971B2 (ja) * 2022-10-18 2025-09-10 株式会社オルトメディコ 糖尿病境界域者のスクリーニング方法
WO2024097429A1 (en) * 2022-11-05 2024-05-10 Texas Tech University System Methods and tools for assessing cardiometabolic health and hidden disease risk among apparently healthy individuals

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
JP2003530130A (ja) 2000-04-14 2003-10-14 メタボロン インコーポレイテッド メタボロミクスを使用した薬物発見、疾患の処置、及び診断のための方法
EP1718327B1 (en) * 2003-06-20 2015-01-07 University of Florida Biomarkers for differentiating between type 1 and type 2 diabetes
US7682782B2 (en) 2004-10-29 2010-03-23 Affymetrix, Inc. System, method, and product for multiple wavelength detection using single source excitation
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
WO2007110357A2 (en) * 2006-03-24 2007-10-04 Metanomics Gmbh Means and method for diagnosing diabetes
MX2010000414A (es) * 2007-07-17 2010-04-01 Metabolon Inc Biomarcadores para prediabetes, enfermedades cardiovasculares y otros trastornos relacionados con sindrome metabolico, y metodos de uso de los mismos.
WO2010005982A2 (en) * 2008-07-07 2010-01-14 The General Hospital Corporation Multiplexed biomarkers of insulin resistance
WO2010007106A1 (en) * 2008-07-15 2010-01-21 Metanomics Health Gmbh Means and methods diagnosing gastric bypass and conditions related thereto
JP2012522989A (ja) * 2009-03-31 2012-09-27 メタボロン インコーポレイテッド インスリン抵抗性に関連するバイオマーカー、及びそれを使用する方法
US8367418B2 (en) 2009-10-23 2013-02-05 Therasyn Sensors, Inc. Method and system to provide personalized pharmaceutical compositions and dosages
EP2494364A1 (en) * 2009-10-29 2012-09-05 Tethys Bioscience, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
WO2013059234A1 (en) * 2011-10-18 2013-04-25 Metabolon, Inc. Biomarkers for amyotrophic lateral sclerosis and methods using the same
EP2776832A4 (en) * 2011-11-11 2015-06-03 Metabolon Inc BIOMARKER FOR BUBBLE CANCER AND METHOD FOR ITS USE
EP2788763A4 (en) * 2011-12-09 2015-10-07 Metabolon Inc BIOMARKERS FOR KIDNEY CANCER AND METHOD FOR USE THEREOF

Similar Documents

Publication Publication Date Title
Vaes et al. Changes in physical activity and all-cause mortality in COPD
Kim et al. Prevalence of metabolic syndrome is higher among non-obese PCOS women with hyperandrogenism and menstrual irregularity in Korea
Nygaard et al. Irisin in blood increases transiently after single sessions of intense endurance exercise and heavy strength training
ter Horst et al. Methods for quantifying adipose tissue insulin resistance in overweight/obese humans
Henderson et al. How are physical activity, fitness, and sedentary behavior associated with insulin sensitivity in children?
ES2669620T3 (es) Biomarcadores relacionados con el avance de la resistencia a la insulina y métodos que lo utilizan
Durrer et al. Differential impact of acute high-intensity exercise on circulating endothelial microparticles and insulin resistance between overweight/obese males and females
Reijnierse et al. The association between parameters of malnutrition and diagnostic measures of sarcopenia in geriatric outpatients
Roumen et al. Predictors of lifestyle intervention outcome and dropout: the SLIM study
Pietrobelli et al. Adipose tissue and metabolic effects: new insight into measurements
Warrington et al. Modelling BMI trajectories in children for genetic association studies
García-Hermoso et al. Fatness mediates the influence of muscular fitness on metabolic syndrome in Colombian collegiate students
Zagatto et al. Relationship between anaerobic capacity estimated using a single effort and 30-s tethered running outcomes
Aerenhouts et al. Estimating body composition in adolescent sprint athletes: Comparison of different methods in a 3 years longitudinal design
Scott et al. The intensity of a resistance exercise session can be quantified by the work rate of exercise
Jayasinghe et al. Fitter women did not have attenuated hemodynamic responses to psychological stress compared with age-matched women with lower levels of fitness
Boghosian et al. Risk factors for developing Perthes disease: a comprehensive national analysis spanning 2 decades
Golec et al. Relationship between anthropometric and body composition parameters and anti-SARS-CoV-2 specific IgG titers in females vaccinated against COVID-19 according to the heterologous vaccination course: A cohort study
Espinosa-Flores et al. A scoping review of the methods used in patients with liver cirrhosis to assess body composition and their nutritional findings
Tee et al. Effects of exercise modality combined with moderate hypoxia on blood glucose regulation in adults with overweight
Robertson et al. A glossary for social-to-biological research
Zuniga et al. The effect of different exercise protocols and regression-based algorithms on the assessment of the anaerobic threshold
Taylor et al. Exercise induces time-dependent but not sex-specific transcriptomic changes in healthy human skeletal muscle
Vollrath et al. Acute Adrenal Suppression Following Resistance Training in Elite Female Athletes: A Comprehensive Steroid Profile
Dunican Seeing the forest for the trees: fractal dimensions measure COPD airway remodeling